Evoq Remedies FY26: Auditor Raises Serious Red Flags

Evoq Remedies reported a net loss of ₹0.24 crore for the year ended March 31, 2026. The company's audited financial results were accompanied by significant concerns from its statutory auditor.

Reader Takeaway: Qualified audit opinion and SEBI probe create high risk; lack of internal controls obscures financial health.

What just happened

Evoq Remedies Limited posted a net loss of ₹0.24 crore on revenues of ₹25.51 crore for the fiscal year 2026. The company's statutory auditor, H Thakkar & Co. LLP, issued a 'Qualified Opinion', highlighting several critical issues.

Why this matters

The qualified opinion signals serious doubts about the company's financial reporting and operational viability. Key concerns include a material uncertainty regarding its ability to continue as a going concern, non-compliance with loan regulations, unconfirmed balances, and a lack of internal controls. Additionally, SEBI is investigating the utilization of funds from a preferential issue, adding regulatory pressure.

The backstory

Evoq Remedies has faced challenges related to financial transparency and regulatory compliance. The auditor's report points to a history of issues, including cash losses and curtailed operations. The current SEBI investigation into preferential issue funds is a significant development.

What changes now

Investors face increased uncertainty. The auditor's report and ongoing SEBI investigation necessitate closer scrutiny of the company's disclosures and future actions. Management claims they are taking steps to improve compliance.

Risks to watch

Key risks include the company's ability to address the going concern issue, the outcome of the SEBI investigation, potential penalties for regulatory non-compliance, and the impact of unverified balances on financial statements. The lack of an internal auditor and audit trail is a major governance concern.

Peer comparison

While specific peer performance data is not provided in the filing, companies facing similar auditor qualifications and regulatory investigations typically experience heightened stock volatility and investor caution.

Context metrics (time-bound)

• Revenue from Operations (FY26): ₹25.51 crore
• Net Loss (FY26): ₹0.24 crore
• Total Assets (FY26): ₹51.94 crore
• Total Liabilities (FY26): ₹7.64 crore
• Related Party Loans: ₹6.70 crore outstanding
• Unconfirmed Debtors Balance: ₹3.85 crore
• Unconfirmed Advances to Suppliers: ₹12.51 crore
• Contested GST Demand: ₹6.55 crore
• Outstanding Income Tax Demand: ₹1.88 crore
• SEBI Summons: July 2024
• SEBI Show Cause Notice: November 2024

What to track next

Investors should closely monitor the company's response to the auditor's observations, updates on the SEBI investigation, and any steps taken to appoint an internal auditor and implement robust internal controls.